$0.72
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 127 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Country

US

CEO

Mr. Marvin Slosman

IPO date

2013

Employees

127

ISIN

US45779A8466

Key stats

Open

$0.71

Volume

108.36K

Market cap

$33.35M

Prev. close

$0.71

Impl / hst vl

-

Open interest

$0.00

$0.67

Day’s Range

$0.72

$0.63

52W Range

$1.98

Valuation

72
Valuation score
Undervalued
P/E
-
P/S
2.99
P/B
0.74
Current ratio
5.15
Debt / Equity
-0.26
ROE
-112.04%
Gross margin
20.22%
Income growth
16.39%
FCF growth
28.62

Analysts estimates

Consensus rating
Buy

The average rating from top 6 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$3.74
The top 5 analysts forecasts that 12-month price may increase by 419.45%, with a low of $3.03 and a high of $4.20
$3.03
Low
$3.74
Avg
$4.20
High
Current price

Earnings

Q1 ‘26 revenue
$3.40M
Q1 ‘26 net income
-$13.69M
Revenue
Net income
Previous EPS
-$0.16
Estimate EPS
-$0.20
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply